Sirolimus-eluting stents are not cost-effective compared with bare-metal stents
This article has no abstract so we have provided the first paragraph of the full text.
The RESEARCH registry includes data from patients fitted with either sirolimus-eluting stents (SESs; n = 508) or bare-metal stents (BMSs; n = 450) between October 2001 and October 2002. Previously published results demonstrated a reduction in the incidence of target vessel revascularization procedures in the SES group compared with the BMS group after 1 and 2 years of follow-up; similar rates of mortality and myocardial infarction were documented in the two groups.
Full text of this article is available with one of the following:
- Personal subscription Purchase your own personal subscription to this journal. Already a subscriber? Please log in for immediate access.
- 7 day single article pass for US$18 In order to purchase this article you must be a registered user. Please register or log in.
- Site licence Learn more about institutional site licences
Current Subscribers
Please log in to access the full text article using the login box at the top of the page.
